(Q34655046)
Statements
1 reference
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma (English)
1 reference
Dirk Schadendorf
1 reference
Paolo A Ascierto
1 reference
Georgina V Long
1 reference
Antoni Ribas
1 reference
Ester Simeone
1 reference
David Minor
1 reference
Celeste Lebbe
1 reference
Anne O'Hagan
1 reference
Niki Arya
1 reference
Mary Guckert
1 reference
Richard F Kefford
1 reference
Jean-Jacques Grob
1 reference
Omid Hamid
1 reference
Ravi Amaravadi
1 reference
Tabea Wilhelm
1 reference
Kevin B Kim
1 reference
Anne-Marie Martin
1 reference
Jolly Mazumdar
1 reference
Vicki L Goodman
1 reference
Uwe Trefzer
1 reference
5 August 2013
1 reference
1 reference
Identifiers
1 reference